Skip to main content
Equibles
OGEN logo

OGEN · Oragenics Inc

Track OGEN — free

Use OGEN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OGEN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.46 -0.01 (-1.51%) At close · Oct 9
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on these factors, there is substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$2.06M
Shares
4.51M
Volume · Oct 9 28.22K Avg daily vol (3M) 29.57K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.46 Open$0.47 Day$0.45–0.48 52W close$0.46–1.39 Avg vol 30d32K Short int842K · 18.7% float · 24.9d Short vol40% DataJan 2020–Oct 2026 Filing10-Q · Aug 13

Up next

Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$37,653
Trailing 12 months
Net income (TTM)
−$10.08M
Trailing 12 months
Revenue growth YoY
-71.4%
Year over year
Operating margin
-55,519.9%
Trailing 12 months
P / E (TTM)
0.4
Trailing earnings · reciprocal yield 243.4%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+505.1%
Year over year · more shares
Price change (1Y)
-67.2%
Trailing year
Short interest
18.7%
Latest settlement · 24.9 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.8 · calm Equity put/call 0.56
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −29%
below
Price vs 50-day avg −11%
below
RSI (14) 40
neutral
MACD trend Negative
52-week position 0%
near low
Momentum
relative strength
Very Weak
1-month return −5%
trailing
6-month return −36%
trailing
YTD return −42%
this year
Relative strength −46%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Flat
1 of 18 funds reported for Sep 30 · net 0 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
18.65% of float · ▲ +4.4% MoM · 24.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
18 holders — mid 3-yr range
Squeeze score 73
high risk · 0–100
Fundamentals
Weak
Revenue growth −9%
Y/Y
Gross margin 0%
EPS growth +90%
Y/Y
Free cash flow $-9.4M
Quant / Vol
risk profile
Very High
Volatility 68%
annualized · 1-yr
Max drawdown −67%
past year
ATR 6.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−29% Bearish
Price vs 50-day avg
−11% Bearish
RSI (14)
40 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Flat
1 of 18 funds reported for Sep 30 · net 0 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
18.65% of float · ▲ +4.4% MoM · 24.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
18 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $1
vs 200-day avg -29% vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
OGEN
Oragenics Inc
this stock
$2.06M -41.5% -8.9% — 18.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $129.29B +12.5% +46.2% 29.7 1.8%
MRNA
Moderna, Inc.
 $89.83B +663.0% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $76.86B -3.3% +20.8% 18.5 2.1%
CSLLY
Csl Ltd
 $61.83B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders
Holders
18
% held
1.5%
Reported
1 of 18
Top holder
GEODE CAPITAL MANAGEMENT,…
Held Float
View
Held by Funds
Fund positions
1
View
Short & Settlement
Short Interest Rising
Shares short
841.6K
Days to cover
24.9d
Change
+35.1K sh
View
Short Volume
Short vol %
40%
As of
Oct 9, 2026
Short Total
View
Fails to Deliver
FTD shares
582
Value
$308
As of
Aug 17, 2026
View
Off-Exchange
Off-exchange %
64.6%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$37.7K
Net income (FY)
$-9.8M
EPS diluted
$-4.56
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 16, 2026
This year
14
View
Proposed Sales
Value
$22
Shares
66
Filed
Dec 6, 2024
View
Exempt Offerings
Offering
$850.0K
Filed
Aug 8, 2023
View

Performance

5D 20D 120D MTD YTD
OGEN -6.5% -5.0% -35.8% -7.3% -41.5%
SPY +1.2% +1.9% +9.9% +2.1% +14.2%
vs SPY -7.6% -6.9% -45.6% -9.4% -55.7%
Key facts CIK 1174940 CUSIP 684023609 13F (30d) 1 filings 1 filers Visit website Investor relations